Dose Insider / Glossary / Topiramate

TopiramateWhat it is, what it treats and why it is in Qsymia

Updated November 20, 2026 路 3 min read 路 MedlinePlus 2026, QSYMIA prescribing information

Topiramate is an anticonvulsant used to treat certain types of seizures and to prevent migraine headaches. MedlinePlus says it works by decreasing abnormal excitement in the brain. It is not used to relieve a migraine once it has started.

20%Tingling of the skin, side effects on Qsymia
Side effects on QsymiaTop dose against placebo, % of adultsTingling of the skin20%Dry mouth19%Change in taste9%Placebo, tingling2%Side effects on QsymiaTop dose against placebo, % of adultsTingling of the skin20%Dry mouth19%Change in taste9%Placebo, tingling2%

Tingling and taste changes are typical of topiramate.

On this page

Combined with phentermine it is one of the two ingredients of Qsymia, a capsule approved for weight management, and loss of appetite and weight loss are among its own listed side effects. It is not a GLP-1 medicine.1,2

How it is used on its own

Topiramate comes as a tablet, a sprinkle capsule whose beads can be swallowed whole or sprinkled on food, extended-release capsules and a liquid. MedlinePlus notes that it is sometimes also used for alcohol dependence, binge eating disorder and essential tremor, uses outside its approved ones that should be discussed with a doctor.1

Topiramate in Qsymia

Qsymia pairs phentermine with extended-release topiramate in one capsule taken in the morning. The strengths are written as pairs, phentermine first: the start is 3.75 mg/23 mg, the usual dose 7.5 mg/46 mg and the top dose 15 mg/92 mg. The top dose is not stopped all at once, because a sudden stop may cause a seizure.2

In the year-long trial in adults with obesity, weight fell by 10.9% on the top dose and 5.1% on the starting dose, against 1.6% on placebo.2 The label reports the pair, not topiramate alone.

The pregnancy risk

The most serious warning concerns pregnancy. The Qsymia label says topiramate taken in the first trimester raises the risk of major birth defects, including cleft lip and cleft palate, and of a baby being small for its gestational age. Qsymia is ruled out in pregnancy. For anyone who can become pregnant, the label recommends a negative pregnancy test before starting and every month during treatment, along with effective contraception, and it is sold only through a restricted program.2

Contraception itself needs care. MedlinePlus warns that topiramate may make hormonal birth control less effective, whether pills, patches, rings or injections, and that another method is needed.1 Some GLP-1 medicines raise a related issue for a different reason, by slowing the stomach; our page on Zepbound and birth control explains it.

Side effects and other warnings

MedlinePlus lists numbness, burning or tingling in the hands or feet, slowed reactions, nervousness, weakness, loss of appetite and weight loss, a change in taste, diarrhea and changes in menstrual bleeding.1 On the top dose of Qsymia, tingling of the skin was reported by 20% against 2% on placebo, dry mouth by 19% against 3% and a change in taste by 9% against 1%.2

The Qsymia label adds warnings that come mainly from topiramate:2

MedlinePlus asks people to call a doctor at once for vision changes or eye pain, a rash or swelling of the face, worse seizures, and confusion or memory problems.1 It also asks people to tell the doctor about any personal or family history of kidney stones, and notes that aspirin and other anti-inflammatory painkillers such as ibuprofen may interact with topiramate.1

Topiramate next to a GLP-1

The two work in different ways: topiramate acts on brain excitability, while GLP-1 medicines act on a gut hormone receptor. Their side effects overlap less than one might expect. Tingling and changes in taste are typical of topiramate, while nausea and other stomach complaints dominate on GLP-1 medicines.2,3 Our page on nausea on a GLP-1 covers the latter.

Sources

  1. MedlinePlus. Topiramate. U.S. National Library of Medicine; last revised May 15, 2026, read November 20, 2026. medlineplus.gov
  2. QSYMIA (phentermine and topiramate extended-release capsules) prescribing information. Vivus LLC; DailyMed, U.S. National Library of Medicine, version published April 24, 2026; sections 2, 4, 5, 6.1 and 14. dailymed.nlm.nih.gov
  3. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 6.1. accessdata.fda.gov

Related analyses

Log your medicines, weight and symptoms together in one place.

Open Dose Insider